Welcome to our dedicated page for Axogen news (Ticker: AXGN), a resource for investors and traders seeking the latest updates and insights on Axogen stock.
Axogen, Inc. develops and commercializes surgical solutions for peripheral nerve regeneration and repair. The company’s recurring updates center on its portfolio for restoration of peripheral nerve function, including Avance® (acellular nerve allograft-arwx), Avance® Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix™.
Company news also includes quarterly and annual financial results, revenue guidance, gross margin and cash metrics, investor-conference participation, FDA-related developments for Avance, and capital-structure actions involving common stock. These updates connect operating performance with Axogen’s commercial activity in nerve repair products across its target markets.
Axogen, Inc. (NASDAQ: AXGN) announced that Karen Zaderej, CEO and chairman, will present at the Jefferies Virtual Healthcare Conference on June 3, 2020, at 2:00 p.m. ET. The presentation will be available via a live webcast on the company’s Investors page and can be replayed for 90 days after the event. Axogen focuses on innovative surgical solutions for peripheral nerve damage, with a portfolio that includes products like Avance® Nerve Graft and Axoguard® Nerve Protector, aimed at restoring nerve function and improving patient quality of life.
Axogen, Inc. (NASDAQ: AXGN) reported Q1 2020 net revenue of $24.3 million, a 4% increase from Q1 2019. However, gross margin declined to 80.1%. The company posted a net loss of $8.2 million or $0.21 per share, compared to a loss of $9.5 million in the same quarter last year. Active accounts rose by 13% to 825. Due to COVID-19, the company suspended its 2020 guidance, foreseeing reduced revenues. Additionally, Axogen returned a $7.8 million PPP loan amid changing eligibility standards. A class action lawsuit was dismissed, and cost-cutting measures were implemented.